The clinical usefulness of the tumor markers; AFP, CEA, CA 125, CA 19-9 in patients with gastric cancer

İn this study, we aimed to investigate; diagnostic usefulness and sensitivity-specisifity values of some of the tumor markers (such as:CEA, CA 19-9, CA 125, and AFP) in totally 112 patients (75 male, 37 female) with gastric cancer. Gastric cancer group; the 57 patients (38 male, 17 female) mean age 55.36±1.37 years, benign disease group; the 30 patients (20 male, 10 female) mean age 53.53+1.97 years, control group; the 25 healtly (17 male, 8 female) mean age 57.11 ±2.87 years. No statistical significant difference was found betvveen the groups for age and sex (p>0.05). Preoperative tumor marker values; CEA, CA 125 and CA 19-% levels in gastric cancer group were found to be highly significiant among benign disease and control groups (p<0.05). Postoperative tumor marker values; CA 125 and CA 19-9 levels in gastric cancer group were found to be highly significant control group (p<0.05), but only CA 125 level were found to be highly significant benign disease group (p<0.05). Preoperative tumor marker value; No statistical significant difference was found between benign disease group and control group from ali of the tumor marker levels (p>0.05). Postoperative tumor marker values; CA 19-9 levels in benign disease group were found to be highly significant control group (p<0.01). The sensitivity and specificity of AFP were 3.5-100%, sensitivity and specificity of CEA were 63-100%, sensitivity and specificity of CA 125 were 35-96%, sensitivity and specificity of CA 19-9 were 47-100% in gastric cancer, respectively. İn conclusion, tumor markers, especially CA 125 and CA 19-9 can be used in clinical applications (e.g. diagnosis, preoperative evaluation and follow up ete.) of gastric cancers.